Table 2 Xenograft regression.

From: Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer

% Regression

VEH

NCK

OSI

N + O

CRI

N + C

Complete Response (100%)

0

33

0

83

17

50

Partial Response (>50%)

0

17

33

17

17

50

Disease Progression

100

50

67

0

66

0

  1. Statistics of regression (%) of xenograft in mice receiving NCK (NCK), Crizotinib (CRI) and OSI-930 (OSI) or combinations group.
Back to article page